WS Canlife UK Equity Fund



Asset Management™


About the fund

The Fund aims to achieve capital growth, over any five-year period, after all costs and charges have been taken. The Fund's comparator benchmark is the Bloomberg UK Large, Mid & Small Cap Total Return Index.



Fund performance

5 Years or since inception for funds with less than 5 years performance.



■ WS Canlife UK Equity Fund ■ Bloomberg UK Large, Mid & Small Cap Total Return Index

Cumulative performance

To 30/04/24 (%)

	1 month	3 months	1 year	3 years	5 years
Fund	2.77	7.39	6.76	24.14	28.04
Comparator Benchmark	2.48	7.46	6.74	24.33	27.67

Discrete year performance

To 31/03/24 (%)

			31/03/2021 31/03/2022		
Fund	7.56	2.23	14.42	32.90	-22.76
Comparator Benchmark	7.96	2.96	13.91	25.16	-19.33

Share class information

Share Class	ISIN	SEDOL	OCF	АМС	Minimum Initial	Minimum top up*
C Acc	GB00B9J7KW65	B9J7KW6	0.80%1	0.75%	£500	£100

^{1 -} The fund incurs transaction costs as a necessary part of buying and selling underlying investments in order to achieve the investment objective. The Ongoing Charges Figure for regulated funds does not include these costs. Details of these costs and how they are incurred are available upon request.

Fund facts Launch date 21/10/2013 Name of fund Nigel Kennett manager Name of fund Rino Shala manager £543.5m Fund size Number of holdings Open Ended Legal structure Investment Company Dealing frequency Daily (Midday) 16th Feb and 16th Ex-dividend date 15th Apr and 15th Distribution date Oct GBP Base currency Bloomberg UK Large, Mid & Small Benchmark Cap Total Return IA UK All Companies Sector Yield Historic: 2.64% Waystone Authorised Management (UK) Corporate Director Ltd, authorised and regulated by the FCA


Fund statistics

	3 years
Standard Deviation	11.85
Sharpe Ratio	0.45
Alpha	-0.29
Beta	1.07
Tracking Error	2.83
Information Ratio	-0.02

Statistical calculations are annualised and based on last 36 months total return performance against the fund benchmark. Source Data: Morningstar

request.
*Minimum investments only apply when investing directly through the Authorised Corporate Director

Sector breakdown



Top 10 holdings Astrazeneca Plc 9.4% Shell 8.0% Unilever Plc 5.9% GSK 4.0% BP Plc 3.8% **HSBC** Holdings Plc 3.8% Relx Plc 2.9% Barclays Plc 2.7% Glencore 2.7% Lloyds Banking Group Plc 2.6%



Risk warning

Due to the underlying assets held, the price of the fund is classed as having above average to high volatility as at 20 February 2023.

This document is issued for information only by Canada Life Asset Management. This document is intended to be used as a sales aid and does not constitute a direct offer to anyone, or a solicitation by anyone, to subscribe for shares or buy units in fund(s). Subscription for shares and buying units in the fund(s) must only be made on the basis of the latest Prospectus and the Key Investor Information Document (KIID) available at www.canadalifeassetmanagement.co.uk. No guarantee, warranty or representation (express or implied) is given as to the document's accuracy or completeness. Data Source - © 2023 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The comparator benchmark assists investors with evaluating the fund's performance against UK equity returns. This benchmark has been chosen as it is believed to be appropriate given the fund's investment objective and policy.

For full details of the fund's risks, please see the latest prospectus and the Key Investor Information Document (KIID). Other share classes are available.